More cancer treatment or comfort care

    Whether to start or continue another round of chemotherapy or immunotherapy when cancer is advanced and options are narrowing, or to focus on comfort care.

    Adults with advanced or metastatic solid cancer whose disease has grown despite earlier treatment. The studies are mostly from the US.

    SourcedModeledNo projected outcomes are generated on this page.

    Pending clinical review. Each statement is paraphrased from the named source, but no clinician has reviewed this page yet. Use it to prepare questions, not to choose a treatment.

    What this decision concerns

    Chemotherapy for metastatic lung or colorectal cancer can extend life by weeks or months and may relieve symptoms, but it does not cure the cancer.

    SourcedUS national prospective cohort study (CanCORS) · 2012

    American Society of Clinical Oncology guidelines recommend palliative chemotherapy only for people with solid tumors whose day-to-day functioning (performance status) is good.

    SourcedUS multicenter prospective cohort study · 2015

    The options

    Start or continue cancer treatment

    Another round of chemotherapy, immunotherapy or targeted therapy, alongside symptom care.

    • In trials of advanced esophageal and gastric cancer, 81.3% of treatment groups kept overall health status stable over time.

      Applies to: 43 randomized trials, 13,727 people with advanced esophageal or gastric cancer. Not limited to the last months of life.

      SourcedSystematic review and meta-analysis · 2020

    • After first-line treatment, single-drug taxane chemotherapy and several targeted drugs improved quality of life compared with supportive care alone.

      Applies to: 43 randomized trials, 13,727 people with advanced esophageal or gastric cancer. Not limited to the last months of life.

      SourcedSystematic review and meta-analysis · 2020

    • Among people who were still functioning well, those on chemotherapy had worse quality of life in their last week than those not on it (odds ratio 0.35).

      Applies to: 312 US adults with progressive metastatic cancer after at least one chemotherapy regimen, followed until death. Observational.

      SourcedUS multicenter prospective cohort study · 2015

    • 14% of people on palliative chemotherapy had CPR or a breathing machine in their last week, compared with 2% of those not on it.

      Applies to: 386 US adults with metastatic cancer that had not responded to at least one regimen, judged terminally ill, who died. Observational, with statistical adjustment.

      SourcedUS multicenter prospective cohort study · 2014

    • People on palliative chemotherapy more often died in intensive care (11% vs 2%) and less often at home (47% vs 66%).

      Applies to: 386 US adults with metastatic cancer that had not responded to at least one regimen, judged terminally ill, who died. Observational, with statistical adjustment.

      SourcedUS multicenter prospective cohort study · 2014

    • 69% of people with lung cancer and 81% with colorectal cancer on chemotherapy did not report understanding that it was not at all likely to cure them.

      Applies to: 1193 US adults receiving chemotherapy for newly diagnosed stage IV lung or colorectal cancer.

      SourcedUS national prospective cohort study (CanCORS) · 2012

    • People given immunotherapy in their last 30 days enrolled in hospice less often (45% vs 69%) and died in hospital more often (56% vs 29%).

      Applies to: 157 people who received immune checkpoint inhibitors and died, at one US center, 2015 to 2018.

      SourcedUS single-center cohort study · 2019

    • Immunotherapy in the last month was not linked to more emergency visits or hospital stays, but was linked to dying in hospital (43% vs 16%).

      Applies to: 102 people who received immune checkpoint inhibitors and died, at two Irish cancer centers.

      SourcedIrish multicenter retrospective study · 2022

    Focus on comfort care

    No further cancer treatment. Care centers on symptoms, comfort and what matters most, often with hospice.

    • After accounting for clinical setting and functioning, chemotherapy use was not linked to how long people lived.

      Applies to: 312 US adults with progressive metastatic cancer after at least one chemotherapy regimen, followed until death. Observational.

      SourcedUS multicenter prospective cohort study · 2015

    • Survival did not differ between people on and off palliative chemotherapy (hazard ratio 1.11), and those off it were referred to hospice late less often (37% vs 54%).

      Applies to: 386 US adults with metastatic cancer that had not responded to at least one regimen, judged terminally ill, who died. Observational, with statistical adjustment.

      SourcedUS multicenter prospective cohort study · 2014

    • People not on palliative chemotherapy more often died where they wanted to (80% vs 65%).

      Applies to: 386 US adults with metastatic cancer that had not responded to at least one regimen, judged terminally ill, who died. Observational, with statistical adjustment.

      SourcedUS multicenter prospective cohort study · 2014

    • For metastatic lung or colorectal cancer, chemotherapy can add weeks or months of life; focusing on comfort alone gives up that possible gain.

      Applies to: Background statement in a US study of people with newly diagnosed stage IV lung or colorectal cancer.

      SourcedUS national prospective cohort study (CanCORS) · 2012

    Set against what matters to you

    Modeled

    Read from what you saved on this device.

    What sources report about what matters to you

    Nothing yet. Mark what matters to you, and anything the sources say about it shows up here.

    Pulls in two directions

    Nothing so far pulls against anything else.

    Still unknown

    • Nothing is marked as a priority yet, so nothing here is connected to what matters to you. The options and their sources are still readable below.

      Not in the sources here.

    • How palliative chemotherapy affects end-of-life outcomes and whether people reach their goals still needs to be worked out.

      US multicenter prospective cohort study, 2014 statement

    • Most of these studies are observational. People who chose more treatment may have differed in ways the studies could not fully measure.

      Not in the sources here.

    • Newer immunotherapies and targeted drugs work differently by cancer type and genetic features. Whether these findings apply to a specific drug is not answered here.

      Not in the sources here.

    Worth asking

    • What is this treatment meant to do for me: cure, more time, or fewer symptoms, and how likely is that?
    • How well am I functioning day to day, and how does that change what treatment might do?
    • What side effects and visits would it involve, and for how long?
    • If I stop treatment, what care and support would I have, and could I start hospice?
    • If I start, when would we look again at whether it is helping?
    Start with what matters

    How this measures up

    Checked against IPDAS 5.0: 10 met, 1 partly met, 3 not met

    Sets source-backed statements about named options against what the person said matters. Does not meet the development and evaluation standard a patient decision aid requires. Three further stages would be needed to call it a patient decision aid: essential-criteria appraisal, an independent bias appraisal, and an evaluation of what it changes for the people who use it. None has been done. 4 criteria below are not fully met.

    Qualifying criteria

    • MetHealth conditionchecked automatically

      A source-backed description of the health condition or event is recorded separately from the option comparison.

    • MetExplicit decisionchecked automatically

      States the decision: "Whether to start or continue another round of chemotherapy or immunotherapy when cancer is advanced and options are narrowing, or to focus on comfort care."

    • MetTarget audiencechecked automatically

      Names who this is for: "Adults with advanced or metastatic solid cancer whose disease has grown despite earlier treatment. The studies are mostly from the US."

    • MetOptionschecked automatically

      2 options, including an explicit wait-or-decline option.

    • MetBenefitschecked automatically

      5 recorded statements read as supporting an option.

    • MetHarmschecked automatically

      7 recorded statements read as burdening an option.

    • Not metValues clarificationrecorded judgment

      Not assessed. An unassessed criterion is not a met one.

    Bias reduction

    • Partly metBest available evidencechecked automatically

      6 primary sources cited, each paraphrased closely. Dated currentness checks found no final newer edition of any source. That remains a negative currentness finding rather than proof that no update is underway.

    • Not metUser involvement in developmentrecorded judgment

      No patient, caregiver, or clinician took part in developing this journey. No usability or comprehension testing has been run on it.

    • MetNeutral presentation of optionschecked automatically

      Every option carries at least one statement in each direction, so no option is recorded as all upside or all downside.

    • MetComplete citationschecked automatically

      6 sources, each with a full citation, a resolving identifier, a publication date, and the date and route it was read.

    • MetPublication or version datechecked automatically

      Last reviewed 2026-11-14.

    • Not metUpdate policyrecorded judgment

      Each journey records when it was last reviewed. A recheck cadence and triggers are proposed, and source recheck due dates are computed from them, but no owner has adopted the policy. This stays unmet until one does.

    • MetFunding disclosedrecorded judgment

      Funding and editorial independence are stated at /independence.

    Screening decisions

    • Not applicableWhat the test measureschecked automatically

      This journey is not a screening decision.

    • Not applicableConsequences of a positive resultchecked automatically

      This journey is not a screening decision.

    • Not applicableNext steps after either resultchecked automatically

      This journey is not a screening decision.

    • Not applicableOverdiagnosis and false positiveschecked automatically

      This journey is not a screening decision.

    This checks the seven IPDAS 5.0 qualifying criteria, seven bias-reduction criteria, and four screening-specific criteria against what each journey holds. IPDAS 5.0 contains more than these. A criterion absent here has not been assessed and is not passed. Standard: IPDAS 5.0, published 2026-06-12. Assessment is by Values in Care, not by IPDAS or any outside reviewer.

    Sources

    Sourced
    • Prigerson HG, Bao Y, Shah MA, et al. Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncol. 2015;1(6):778-784.

      https://doi.org/10.1001/jamaoncol.2015.2378

      Read 2026-11-14 from the PubMed record (structured abstract of the version of record).

      Currentness check · 2026-11-14

      A primary study is not superseded by later studies; later work adds to it rather than replaces it.

      Method: PubMed record review via the PubMed MCP connector.

      Not covered: Corrections or later reanalyses were not searched for separately.

    • Wright AA, Zhang B, Keating NL, et al. Associations between palliative chemotherapy and adult cancer patients' end of life care and place of death: prospective cohort study. BMJ. 2014;348:g1219.

      https://doi.org/10.1136/bmj.g1219

      Read 2026-11-14 from the PubMed record (structured abstract of the version of record).

      Currentness check · 2026-11-14

      A primary study is not superseded by later studies; later work adds to it rather than replaces it.

      Method: PubMed record review via the PubMed MCP connector.

      Not covered: Corrections or later reanalyses were not searched for separately.

    • Weeks JC, Catalano PJ, Cronin A, et al. Patients' expectations about effects of chemotherapy for advanced cancer. N Engl J Med. 2012;367(17):1616-1625.

      https://doi.org/10.1056/NEJMoa1204410

      Read 2026-11-14 from the PubMed record (structured abstract of the version of record).

      Currentness check · 2026-11-14

      A primary study is not superseded by later studies; later work adds to it rather than replaces it.

      Method: PubMed record review via the PubMed MCP connector.

      Not covered: Corrections or later reanalyses were not searched for separately.

    • Glisch C, Hagiwara Y, Gilbertson-White S, et al. Immune checkpoint inhibitor use near the end of life is associated with poor performance status, lower hospice enrollment, and dying in the hospital. Am J Hosp Palliat Care. 2020;37(3):179-184.

      https://doi.org/10.1177/1049909119862785

      Read 2026-11-14 from the PubMed record (structured abstract of the version of record).

      Currentness check · 2026-11-14

      A primary study is not superseded by later studies; later work adds to it rather than replaces it.

      Method: PubMed record review via the PubMed MCP connector.

      Not covered: Corrections or later reanalyses were not searched for separately.

      Adjacent evidence, not incorporated into this journey: Wheless et al., Cancer Med 2025 (PMID 41070975), found similar end-of-life outcomes but higher health care use with immunotherapy as the last treatment in advanced liver cancer. A clinical reviewer should decide whether it belongs in this journey.

    • O'Sullivan HM, Conroy M, Power DG, et al. Immune checkpoint inhibitors and palliative care at the end of life: an Irish multicentre retrospective study. J Palliat Care. 2025;40(2):147-151.

      https://doi.org/10.1177/08258597221078391

      Read 2026-11-14 from the PubMed record (structured abstract of the version of record).

      Currentness check · 2026-11-14

      A primary study is not superseded by later studies; later work adds to it rather than replaces it.

      Method: PubMed record review via the PubMed MCP connector.

      Not covered: Corrections or later reanalyses were not searched for separately.

    • van Kleef JJ, Ter Veer E, van den Boorn HG, et al. Quality of life during palliative systemic therapy for esophagogastric cancer: systematic review and meta-analysis. J Natl Cancer Inst. 2020;112(1):12-29.

      https://doi.org/10.1093/jnci/djz133

      Read 2026-11-14 from the PubMed record (structured abstract of the version of record).

      Currentness check · 2026-11-14

      No later systematic review of quality of life during palliative systemic therapy across tumor types was identified among the results reviewed.

      Method: PubMed search via the PubMed MCP connector for later systematic reviews of the same question.

      Not covered: Only the first results were reviewed; tumor-specific reviews, such as pancreatic cancer, were not assessed.

    Each clinical statement above paraphrases one of these sources closely. Filing it under a priority, or reading it against priorities you saved, is a Values in Care editorial operation rather than a source finding.

    Open Source Watch